Allogeneic stem cell transplantation (allo-SCT) after a reduced-intensity conditioning (RIC) protocol is associated with decreased short-term toxicity. This suggests that the procedure could be performed on an outpatient basis. We analysed the incidence and risk factors of grade X2 conditioning-related toxicities (CRTs) as a hallmark for hospital admission, in 41 consecutive patients allografted from an HLA identical sibling after RIC. The RIC regimen consisted of fludarabine plus melphalan for lymphoid malignancies, and fludarabine plus busulphan for myeloid malignancies. In all, 11 patients (27%) did not experience any toxicity. The more frequent CRTs observed were neutropenic fever and gastrointestinal toxicity. The median duration of hospitalisation was 27 (range, 17-50) days. If allo-SCT had been planned as an outpatient procedure and admission indicated only in the case of X2 CRTs, the inpatient period would have decreased to 9 (range, 0-33) days (Po0.001). No risk factors for CRTs were identified. Allo-SCT after an RIC regimen is a well-tolerated procedure. Our results warrant a prospective pilot trial of nonmyeloablative allo-SCT performed in the outpatient setting.
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Allogeneic stem cell transplantation (allo-SCT) has been successfully used to treat patients with a variety of haematological disorders. Despite improvements made in the prevention and control of conditioning-related toxicities (CRTs), transplant-related morbid mortality remains high. Post transplant complications are especially frequent in heavily treated and in elderly patients.
In an effort to decrease the toxicity associated with allo-SCT, reduced-intensity conditioning (RIC) regimens have been developed. 1, 2 The use of these less toxic regimens permits expansion of the indications for allo-SCT to patients otherwise excluded from this procedure. 3 Some authors have also suggested that this approach, as it is well tolerated, could be performed in the outpatient setting. 4, 5 We investigated the CRTs after RIC allogeneic transplantation at our institution. We tested the hypothesis of whether this procedure could potentially be carried out totally or partially in an outpatient basis. We compared real hospitalisation length with the number of calculated inpatient days if allo-SCT had been performed in the Outpatient Department (OPD), using the development of grade X2 CRT as the hallmark for hospital admission.
Patients and methods

Patients
Between July/1999 and October/2001, 41 consecutive patients (28 males, 13 females with a median age of 52 (range, 26-64) years) with haematological malignancies received an allo-SCT from an HLA identical sibling, after a RIC regimen in our institution. The underlying diseases were acute leukaemia (AL) (n ¼ 12, 29%), non-Hodgkin's lymphoma (NHL) (n ¼ 9, 22%), multiple myeloma (MM) (n ¼ 7, 17%), chronic lymphoid leukaemia (CLL) (n ¼ 5, 12%), Hodgkin's disease (HD) (n ¼ 4) and chronic myelogenous leukaemia (CML) (n ¼ 4). Clinical characteristics of the patients at transplantation are shown in Table 1 . The median time from diagnosis to transplant was 23 (range, 2-125) months.
Transplantation characteristics
All patients were nursed in reversed-barrier isolation in single high-efficiency particulate air-filtered rooms. Patients were hospitalised the day before beginning the conditioning regimen, and were discharged from hospital when haematological and extrahaematological toxicities associated with conditioning had resolved. , with dose adjustment to plasma levels for myeloid malignancies (n ¼ 14). Table 2 shows the dose and treatment schedules for the RIC regimen. Graft-versus-host disease prophylaxis consisted of cyclosporine A plus short-course methotrexate (10 mg/m 2 i.v. on days þ 1, þ 3, þ 6), and infection prophylaxis consisted of norfloxacine 400 mg twice daily p.o., acyclovir 800 mg twice daily p.o. and fluconazole 100 mg once daily p.o. Haematopoietic growth factors were not routinely given after stem cell infusion.
Stem cells were obtained from peripheral blood from genotypically HLA-identical siblings, and collected by a continuous flow cell separator COBE-Spectra. In one case, stem cells were obtained from the donor bone marrow. Peripheral blood stem cells were mobilised with granulocyte colony-stimulating factor at a dose of 10 mg/kg/day. None of the grafts were ex vivo manipulated before infusion. The median number of CD34 þ cells transplanted was 5 (range, 3-9) Â 10 6 /kg.
Follow-up and toxicity
Clinical charts of the patients were reviewed, and the presence of any toxicity grade X2 during the administration of conditioning and until engraftment and hospital discharge was recorded. Any grade X2 toxicity except for haematological toxicity was considered as a hallmark for a theoretical hospital admission if the patient had been maintained in an outpatient setting. Toxicity was graded according to the WHO classification. 6 Specifically, grade 2 toxicity was as follows:
1. Gastrointestinal: stomatitis with ulceration and some limits on eating, occasional and moderate nausea and vomiting, moderate constipation or moderate diarrhoea lasting more than 2 days, increment of bilirubin, AST, ALT, GGT or alkaline phosphatase between 2.6 and 5 times the upper limit of normal. 2. Renal and bladder: increment of creatinine or blood urea nitrogen between 2.6 and 5 times the upper limit normal of gross haematuria without clots. 
Statistical analysis and study definitions
For the purpose of this analysis, early phase was defined as AL or lymphoproliferative disorders in first complete remission, CML in first chronic phase and MM in complete or partial remission after first-line therapy. Advanced stage was considered as AL or lymphoproliferative disorders in second complete remission, or sensitive or resistant relapse after salvage therapy, CML in second chronic phase, accelerated or blastic phases and MM in chemosensitive or resistant relapse after second-line chemotherapy. Potential hospitalisation length if the transplant had been performed in the OPD was calculated from the first day that the patient experienced grade X2 toxicity to the day of hospital discharge. Real hospitalisation length and potential hospitalisation length were compared using the Wilcoxon's rank-sum test.
Several risk factors for developing CRTs were evaluated. Gender, underlying disease, disease status at transplant, number of previous treatments, previous autologous stem cell transplantation (ASCT), the use of busulphan vs melphalan as conditioning and neutropenic status (neutrophil count o0.5 Â 10 9 /l) at the beginning of the conditioning regimen were analysed as categorical variables, whereas age, time from diagnosis, serum creatinine, serum albumin, haemoglobin level and leucocyte and platelet counts before allo-SCT were considered as continuous variables. Comparison of categorical variables was performed by the Fisher's exact test and comparison of continuous variables was performed by the MannWhitney's U-test. All P-values were two-sided, and a value of Pp0.05 was considered significant. 
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Results
Haematological toxicity
All patients experienced severe neutropenia after the RIC regimen. In all, 15 patients (37%) were neutropenic on day 0, while the remaining 26 patients (63%) were not. Of these 26 patients, the median time from stem cell infusion to neutropenia was 4.5 (range, 1-13) days. Median duration of severe neutropenia was 13 (range, 4-27) days for the whole series. In six patients (15%), the platelet count did not decrease below 20 Â 10 9 /l, while 35 patients (85%) developed severe thrombocytopenia of a median duration of 6 (range, 3-23) days. Six patients (15%) did not require packed red blood cell transfusions, and five patients (12%) did not need platelet support.
Neutropenic fever
A total of 29 patients (71%) developed neutropenic fever. The median time from admission to neutropenic fever and from infusion to neutropenic fever were 15 (range, 10-25) days and 6 (range, 1-16) days, respectively. Blood cultures were positive in nine patients. The microorganisms isolated were E. coli (n ¼ 1), Pseudomonas aeruginosa (n ¼ 1), Staphylococcus epidermidis (n ¼ 3) and Staphylococcus coagulase negative (n ¼ 5). Two patients with neutropenic fever developed pneumonia, but there were no deaths related to infectious complications.
Nonhaematological toxicities
In all, 13 patients (32%) developed grade X2 gastrointestinal (GI) toxicity. The most frequent toxicity was mucositis (n ¼ 10, 24%). Two patients developed grade X2 diarrhoea, and one patient developed grade 2 nausea and vomiting. The median time from hospital admission and from stem cell infusion to GI toxicity was 17 (range, 7-22) days and 7 (range, 2-10) days, respectively. We found a relationship between the development of GI toxicity and neutropenic fever. Of the 13 patients who developed GI toxicity, 12 (92%) also developed neutropenic fever. In contrast, 17 of 28 patients (60%) not developing GI toxicity developed neutropenic fever (P ¼ 0.04). Over all, 30 patients (73% of the series) developed neutropenic fever or GI toxicity.
One patient experienced neurological toxicity grade 2 with generalised seizures, and another patient developed secondary diabetes mellitus during the conditioning regimen. No patient experienced veno-occlusive disease. However, one patient developed transient mild hyperbilirubinemia, and two patients experienced a mild increase in creatinine.
Of note, one quarter of the patients did not experience any toxicity at all.
Days of hospitalisation
The median duration of real hospitalisation was 27 (range, 17-50) days. Considering the development of CRTs grade X2 as a hallmark for hospital admission, 11 patients (27%) would never have been hospitalised in the immediate post allo-SCT period. For patients developing CRTs grade X2, if allo-SCT had been performed in the OPD, the inpatient stay would have been reduced to 12 (range, 2-33) days. Globally, if allo-SCT had been performed in the OPD, the inpatient period would have decreased to 9 (range, 0-33) days (Po0.001) (Figure 1 ).
Prognostic factors for CRTs
None of the risk factors studied for the development of CRTs had a statistically significant impact. The use of melphalan in the conditioning protocol was of borderline significance (P ¼ 0.06); 80% of the patients conditioned with melphalan developed neutropenic fever, while this percentage decreased to 50% for patients receiving busulphan. We were not able to demonstrate any relationship between the duration of neutropenica and the development of neutropenic fever.
Discussion
The present descriptive study of allo-SCT following an RIC regimen reveals that this procedure is safe, and has low immediate post transplant toxicity even in elderly and heavily pretreated patients. This fact is remarkable, taking into account that more than one quarter of the patients reported here did not experience any toxicity at all, and there were no short-term transplant-related deaths. Furthermore, an outpatient approach could have reduced the inpatient days in patients experiencing complications from a median of 27 days to 9 days.
Our results are similar to those reported by other authors. [7] [8] [9] [10] However, direct comparisons are not possible due to the use of different conditioning regimens. In our study, the most frequent CRTs were uncomplicated neutropenic fever (71%) and mild GI toxicity (32%). Veno-occlusive disease and renal failure were absent. We did not show any relationship between the duration Low toxicity after reduced-intensity conditioning regimen M Subirà et al of neutropenia and the development of neutropenic fever. In contrast, there was a clear relationship between GI toxicity and the development of neutropenic fever. Our results also confirm that these RIC regimens reduce the duration of post transplantation aplasia and decrease transfusion requirements. 5 In all, 15% of patients did not develop thrombocytopenia, and the median duration of absolute neutropenia was 13 (range, 4-27) days. Nevertheless, one must take into account that our toxicity data were obtained in a population of patients treated in a clean hospital environment, and that they might not be extrapolated to an outpatient setting.
Recently, the Seattle team 4 reported their results in terms of short-term procedure-related toxicity of 45 patients older than 50 years, treated with total body irradiation (200 cGy) before haematopoietic stem cell transplantation. Out of 32 patients, 17 (53%) eligible for outpatient transplantation did not require hospitalisation, and the remainder were hospitalised for a median of 8 (range, 1-35) days. These authors suggested that this procedure could be entirely performed in the outpatient sitting.
In summary, before starting to perform allo-SCT using RIC in an outpatient setting, we investigated the potential safety and advantages of this approach. We have shown that at least one quarter of the patients did not develop any CRT, and that CRTs appeared after a median of 16 days from hospital admission in the remaining patients. These findings give a background to proposing that patients be included in outpatient transplantation programs. This may translate into improved quality of life and be costbeneficial.
